Yasutomi Motoko, Kunishima Shinji, Okazaki Shintaro, Tanizawa Akihiko, Tsuchida Shinya, Ohshima Yusei
Department of Pediatrics, Faculty of Medical Sciences, University of Fukui, 23-3 Shimoaizuki, Matsuoka, Eiheiji, Yoshida, Fukui, 9101193, Japan.
Department of Advanced Diagnosis, Clinical Research Center, National Hospital Organization Nagoya Medical Center, 4-1-1 Sannomaru, Naka-ku, Nagoya, 4600001, Japan.
Ann Hematol. 2016 Jan;95(1):141-144. doi: 10.1007/s00277-015-2517-6. Epub 2015 Oct 10.
Mutations in ACTN1, the gene encoding the actin-crosslinking protein α-actinin-1, cause autosomal dominant macrothrombocytopenia. α-Actinin-1 exists as antiparallel dimers, composed of an N-terminal actin-binding domain (ABD), four spectrin-like repeats (SLRs), which form the spacer rod, and a C-terminal calmodulin-like (CaM) domain. All of the previously reported ACTN1 mutations associated with macrothrombocytopenia reside within the ABD and the CaM domain and not within the SLR domain. In this report, we describe a mutation in SLR2 of α-actinin-1 (p.Leu395Gln) associated with familial macrothrombocytopenia. A 3-year-old boy and his mother both had this mutation. They showed a mild form of thrombocytopenia without severe bleeding, accompanied by an elevated mean platelet volume. Consistent with the previous reports of mutations that reside in the ABD or the CaM domain, immunofluorescence examination revealed disorganization of the actin cytoskeleton in Gln395 mutant-transduced Chinese hamster ovary cells. Our findings suggest a novel mechanism for the pathogenesis of ACTN1-related macrothrombocytopenia that does not involve functional domain mutations.
编码肌动蛋白交联蛋白α-辅肌动蛋白-1的基因ACTN1发生突变会导致常染色体显性遗传性大血小板减少症。α-辅肌动蛋白-1以反平行二聚体形式存在,由一个N端肌动蛋白结合结构域(ABD)、形成间隔杆的四个血影蛋白样重复序列(SLR)以及一个C端钙调蛋白样(CaM)结构域组成。所有先前报道的与大血小板减少症相关的ACTN1突变都位于ABD和CaM结构域内,而非SLR结构域内。在本报告中,我们描述了α-辅肌动蛋白-1的SLR2中一个与家族性大血小板减少症相关的突变(p.Leu395Gln)。一名3岁男孩及其母亲都有此突变。他们表现为轻度血小板减少症,无严重出血,伴有平均血小板体积升高。与先前关于位于ABD或CaM结构域的突变的报道一致,免疫荧光检查显示在转导了Gln395突变体的中国仓鼠卵巢细胞中肌动蛋白细胞骨架紊乱。我们的研究结果提示了一种与ACTN1相关的大血小板减少症发病机制的新机制,该机制不涉及功能结构域突变。